Comparative Screening for Thyroid disorders: in an iodine deficient community: A Retro prospective Study

*M.Nasrollahzadeh, Reza Khodarahmi, Mahmoud Roushani, Amirhassan Amiri, Mahmoud Amouzadeh Tabrizi
Department of Endocrine disorders. Iran

*Corresponding Author : M.Nasrollahzadeh, Department of Endocrinology.

Received date: April 01,2017 Accepted date: September 09,2017 ; Published date: January 01,2018

Citation for this Article : M.Nasrollahzadeh, Comparative Screening for Thyroid disorders: in an iodine-deficient community: A Retro prospective Study. J. Endocrinology and Disorders Doi: 10.31579/2640-1045/015

Copyright : © 2018 M.Nasrollahzadeh . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Thyroid disorders are conditions that affect the thyroid gland, a butterfly-shaped gland in the front of the neck. The thyroid has important roles to regulate numerous metabolic processes throughout the body. Different types of thyroid disorders affect either its structure or function.

The thyroid gland is located below the Adam's apple wrapped around the trachea (windpipe). A thin area of tissue in the gland's middle, known as the isthmus, joins the two thyroid lobes on each side. The thyroid uses iodine to produce vital hormones. Thyroxine, also known as T4, is the primary hormone produced by the gland. After delivery via the bloodstream to the body's tissues, a small portion of the T4 released from the gland is converted to triiodothyronine (T3), which is the most active hormone. The function of the thyroid gland is regulated by a feedback mechanism involving the brain.

2 billion individuals worldwide have insufficient iodine intake, with those in South Asia and sub-Saharan Africa particularly affected. Iodine deficiency has many adverse effects on growth and development. These effects are due to inadequate production of thyroid hormone and are termed iodine-deficiency disorders. Iodine deficiency is the most common cause of preventable mental impairment worldwide. Assessment methods include urinary iodine concentration, goitre, newborn thyroid-stimulating hormone, and blood thyroglobulin. In nearly all countries, the best strategy to control iodine deficiency is iodisation of salt, which is one of the most cost-effective ways to contribute to economic and social development. When iodisation of salt is not possible, iodine supplements can be given to susceptible groups. Introduction of iodised salt to regions of chronic iodine-deficiency disorders might transiently increase the proportion of thyroid disorders, but overall the small risks of iodine excess are far outweighed by the substantial risks of iodine deficiency. International efforts to control iodine-deficiency disorders are slowing, and reaching the third of the worldwide population that remains deficient poses major challenges.

Introduction

Thyroid Disease

The thyroid is a butterfly-shaped gland located in the front of the neck just above the trachea. It weighs approximately 15 to 20 grams in the adult human. The thyroid produces and releases into the circulation at least two potent hormones, thyroxine (T4) and triiodothyronine (T3), which influence basal metabolic processes and/or enhance oxygen consumption in nearly all body tissues. Thyroid hormones also influence linear growth, brain function including intelligence and memory, neural development, dentition, and bone development (Larsen, 2003).

The thyroid gland produces T4 and T3 utilizing iodide obtained either from dietary sources or from the metabolism of thyroid hormones and other iodinated compounds. About 100 µg of iodide is required on a daily basis to generate sufficient quantities of thyroid hormone. Dietary ingestion of iodide in the United States ranges between 200 and 500 µg/day and varies geographically; ingestion is higher in the western part of the United States than in the eastern states. The specialized thyroid epithelial cells of the thyroid gland are equipped with a NaI symporter that helps concentrate iodide 30 to 40 times the level in plasma to ensure adequate amounts for the synthesis of thyroid hormone. The iodine trapped by the thyroid gland is subsequently oxidized to iodine by the enzyme thyroid peroxidase. The iodine then undergoes a series of organic reactions within the thyroid gland to produce tetraiodothyronine or thyroxine (T4) and triiodothyronine (T3).

T3 is also produced in other tissues such as the pituitary, liver, and kidney by the removal of an iodine molecule from T4. T3 is considered to be more of a pro-hormone, while T4 is the most potent thyroid hormone produced. T4 and T3 are both stored in the thyroglobulin protein of the thyroid gland and released into the circulation through the action of pituitary derived thyrotropin (thyroid stimulating hormone or TSH). A normal individual produces from the thyroid gland approximately 90 to 100 µg of T3 and 30 to 35 µg of T4 on a daily basis. An estimated 80 percent of the T3 produced daily in humans is derived from peripheral metabolism (5'-monodeiodination) of T4, with only about 20 percent secreted directly from the thyroid gland itself. On a weight basis, T3 is about 3 to 5 times more potent as a thyroid hormone than T4 and is believed to be the biologically active form of the hormone.

Hyperthyroidism and hypothyroidism are common conditions that have life-long effects on health. About 5 percent of U.S. adults report having thyroid disease or taking thyroid medication. In a cross-sectional study of 2,799 well-functioning adults ages 70 to 79, 9.7 percent of black women, 6 percent of white women, 3.2 percent of black men, and 2.2 percent of white men reported a history of hyperthyroidism. In the same study, 6.2 percent of black women, 16.5 percent of white women, 1.7 percent of black men, and 5.6 percent of white men reported a history of hypothyroidism.

Hyperthyroidism has several causes. Graves' disease, the most common intrinsic cause, is an autoimmune disorder associated with the development of long-acting thyroid stimulating antibodies (LATS).
Single or multiple thyroid nodules that produce thyroid hormones can also cause hyperthyroidism. The use of excessive doses of the thyroid hormone supplement levothyroxine is also a common cause.

**Definition of Screening and Casefinding**

Screening can be defined as “the application of a test to detect a potential disease or condition in a person who has no known signs or symptoms of that condition at the time the test is done.” By this definition, screening with thyroid function tests may identify asymptomatic individuals as well as patients who have mild, nonspecific symptoms such as cold intolerance or feeling “a little tired.”

**Thyroid Function Test**

At the present time, serum-based tests available by immunoassay for measuring the concentration of thyroid hormones in the circulation include total (TT4 and TT3) and free (FT4 and FT3) hormone. In addition, direct measurements of thyroid hormone binding plasma proteins, thyroxine binding globulin (TBG), transthyretin (TTR)/prealbumin (TBPA), and albumin are also available. However, the thyroid test measurement that has the greatest utility for evaluating patients suspected of thyroid disease is the third-generation thyroid stimulating hormone (TSH, thyrotropin) assay. Most third-generation TSH assays today that can reliably detect differences of 0.02 μU/mL or better (interassay imprecision <20% percent) can easily distinguish both hyper- and hypothyroidism from euthyroidism (normal thyroid function) and may differentiate the patient suffering from the “euthyroid sick syndrome” from true hyperthyroidism. Other methods in thyroid testing include the measurement of thyroid gland autoantibodies, including antithyroid peroxidase (TPOab), antithyroglobulin (Tgab), and antibodies against the TSH receptor (Trab). All of these thyroid test methods are routinely available on automated immunoassay instruments located in most hospital and reference laboratories with tight (<10 percent) method between run coefficients of variation.

**Thyroid Function Testing in the Elderly**

The prevalence of both low and high serum TSH levels (with normal serum free T4 results) is increased in elderly subjects compared with younger people. With respect to high serum TSH values, the increase is thought to represent an increased prevalence of autoimmune thyroiditis, especially in women, as will be discussed. The higher prevalence of low serum TSH values may be due to thyroid nodular disease or unrecognized non-thyroid illness.

**Design**

The first screening study where elderly subjects with varying amounts of iodine supply but from the same geographical and ethnographical region (Carpathian basin) were compared, and all hormone measurements and ultrasonography were performed by the same laboratory or person.

**Patients**

Nursing home residents were screened for thyroid disorders from: (A) an iodine-deficient area, Northern Hungary (n=119; median age 81 years; median iodine excretion (MIE) 0.065 μmol/mmol creatinine (equivalent to 72 μg/g creatinine); (B) an area of obligatory iodinated salt prophylaxis since the 1950s, Slovakia (n=135; median age 81 years, MIE 0.090 μmol/mmol creatinine (equivalent to 100 μg/g creatinine)) and (C) an abundant iodine intake area, Eastern Hungary (n=92; median age 78 years; MIE 0.462 μmol/mmol creatinine (equivalent to 513 μg/g creatinine)).

**Measurements**

TSH, T4, free T4, T3, thyroglobulin (Tg), antibodies to Tg (AbTg) and to thyroid peroxidase (AbTPO), iodine excretion, ultrasonography of the thyroid gland.

**Results**

In regions A, B and C, the prevalence of unsuspected clinical hypothyroidism was 0.8%, 1.5% and 7.6% (P = 0.006), with all cases except one being antibody positive (Ab+). The occurrence of subclinical hypothyroidism was 4.2% in region A, 10.4% in region B and 23.9% in region C (P<0.001), but only 3 of 22 cases with subclinical hypothyroidism from region C were Ab+. The overall prevalence of Ab positivity (either antiTg+ or antiTPO+) was similar in the three regions (A, 19.3%; B, 24.4%; C, 22.8%). The occurrence of hyperthyroidism (clinical plus subclinical) was 3.4% in region A, 3.0% in region B and 0% in region C (not significant). The rate of elevated Tg levels was similar in the three regions. The prevalence of goitre was 39.4%, 16.4% and 12.2% (P<0.001), respectively in regions A, B and C. In euthyroid subjects the mean ultrasonographically determined thyroid volume was 21.9 ml in region A, 13.6 ml in region B and 15.1 ml in region C (ANOVA F=5.76, P=0.0038). There was no significant difference in the occurrence of cases with hypoechogenic echotexture of the thyroid gland.

**Accuracy of Screening Tests**

Screening for thyroid dysfunction can be done using a history and physical examination, antithyroid antibodies, or thyroid function tests, including various assays for TSH and T4. Today the TSH test is usually proposed as the initial test in screening because of its ability to detect abnormalities before serum thyroxine and triiodothyronine levels are abnormal. When used to confirm suspected thyroid disease in patients referred to an endocrine specialty clinic, the sensitive TSH has a sensitivity above 98 percent and a specificity greater than 92 percent for the clinical and functional diagnosis. The accuracy of a TSH when used to screen primary care patients has been difficult to evaluate. The greatest difficulty is in classifying a patient who has an abnormal TSH, normal T4 and T3 levels, and no evidence supporting thyroid disease on physical examination. Those who consider the TSH to be the “gold standard” determination of disease would define such a patient as a “true positive.” Others argue that patients who have an abnormal TSH but who never develop complications and never progress should be considered “false positives.” They argue that these patients happen to have TSH levels outside the 95-percent reference limits for the general population but never truly had a thyroid disorder.

**Conclusions**

The screening for hypothyroidism in nursing home residents living in iodine-rich regions is justified by the high prevalence of unsuspected clinical hypothyroidism. The high prevalence of antibody positivity in old age is independent of the iodine supply, but iodine supply has a determining role in the development of autoimmune hypothyroidism in the aged. Most cases of subclinical hypothyroidism in iodine-rich regions are not of autoimmune origin. In old age, hypoechogenic texture of the thyroid gland is not predictive of thyroid dysfunction.

**References**

1. Bilлевicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, et al. 1969. Statistical methods applied to the diagnosis of hypothyroidism. *Q J Med* 38:255–266.

2. Crooks J, Murray I, Wayne EJ. 1959. *Q J Med* 28:211.

3. Eden S, Sundbeck G, Lindstedt G, Lundberg PA, Jagenburg R, Landahl S, et al. 1988. Screening for thyroid disease in the elderly. Serum concentrations of thyrotropin and 3,5,3’-triiodothyronine in a representative population of 79-year-old women and men. *Comp Gerontol* 2:40–45.

4. Helfand M, ed. 1992. *Screening for Thyroid Dysfunction: Rationale, Strategies, and Cost-Effectiveness*. St. Louis: Mosby-Year Book.

5. O’Reilly DS. 2000. Thyroid function tests-time for a reassessment. *BMJ* 320:1332–1334.

6. Danese MD, Powe NR, Sawin CT, Ladenson PW. 1996. Screening for mild thyroid failure at the periodic health examination: A decision and cost-effectiveness analysis. *JAMA* 276:285–292.
7. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, et al. 2000. American Thyroid Association guidelines for detection of thyroid dysfunction. [erratum appears in Arch Intern Med 2001 Jan 22;161(2):284]. Arch Intern Med 160:1573–1575.

8. McDermott MT, Ridgway EC. 2001. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 86:4585–4590.

9. Chu JW, Crapo LM. 2001. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 86:4591–4599.

10. Helfand M, Crapo LM. 1990. Testing for suspected thyroid disease. In: Sox HC, editor. , ed. Common Diagnostic Tests . Philadelphia: American College of Physicians.

11. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W, Cook D, et al. 1996. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 11:744–749.

12. Parle J, Franklyn J, Cross K, Jones S, Sheppard M. 1991. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 34:77–83.

13. Sundbeck G, Jagenburg R, Johansson P-M, Eden S, Lindstedt G. 1991. Clinical significance of a low serum thyrotropin concentration by chemilumminometric assay in 85-year-old women and men. Arch Intern Med 151:549–556.

14. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PWF, Hershman JM. 1991. Low serum thyrotropin (thyroid-stimulating hormone) concentrations in older persons without hyperthyroidism. Arch Intern Med 151:165–168.

15. Attia J, Margetts P, Guyatt G. 1999. Diagnosis of thyroid disease in hospitalized patients. A systematic review. Arch Intern Med 159:658–665.

16. Sundbeck G, Lundberg PA, Lindstedt G, Svanborg A, Eden S. 1991. Screening for thyroid disease in the elderly. Serum free thyroxine and thyrotropin concentrations in a representative population of 81-year-old women and men. Aging (Milano) 3:31–37.

17. Drinka PJ, Amberson J, Voeks SK, Schomisch J, Schirz P, Christensen D. 1996. Low TSH levels in nursing home residents not taking thyroid hormone. J Am Geriatr Soc 44:573–577.

18. Bondeson E, Meisel T, Eggertsen R. 1997. [A simple health control for the elderly. Screening for vitamin B12 deficiency and thyroid disease]. [Swedish]. Lakartidningen 94:4329–4332.

19. Wang C, Crapo LM. 1997. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 26:189–218.

20. Helfand M, Crapo LM. 1990. Screening for thyroid disease. Ann Intern Med 112:840–849.

21. Helfand M, Redfern CC. 1998. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians [published erratum appears in Ann Intern Med 1999 Feb 2;130(3):246]. Ann Intern Med 129:144–158.

22. Kung AW, Janus ED. 1996. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine intake. Thyroid 6:111–114.

23. Danese D. 1997. Subclinical hypothyroidism in flight personnel: Evaluation for suitability to fly. Int Rev Armed Forces Med Serv 70:32–36.

24. Fardella C, Poggi H, Gologer S, Rojas A, Velasquez CG, Barroilhet S, et al. 2001. [High prevalence of subclinical thyroidal disease among individuals attended in health control]. [Spanish]. Rev Med Chil 129:155–160.

25. Chuang CC, Wang ST, Wang PW, Yu ML. 1998. Prevalence study of thyroid dysfunction in the elderly of Taiwan. Gerontology 44:162–167.

26. Knudsen N, Jorgensen T, Rasmussen S, Christiansen E, Perrild H. 1999. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol 51:361–367.

27. Hollowell JG, Stachling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. 2002. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) . J Clin Endocrinol Metab 87:489–499.

28. Kanaya AM, Harris F, Volpato S, Perez-Stable EJ, Harris T, Bauer DC. 2002. Association between thyroid dysfunction and total cholesterol level in an older biracial population: The health, aging and body composition study. Arch Intern Med 162:773–779.

29. Eddy D. 1991. How to think about screening. In: Eddy D, editor. , ed. Common Screening Tests . Philadelphia: American Coll Physicians. Pp.1–21.